Guardant Health Corporation is the company in question (NASDAQ: GH). Research analysts working for William Blair included their projections for the earnings per share that Guardant Health will generate during the fiscal year 2022 in a study published on January 9, 2019. A. Brackmann, an analyst working for William Blair, has made projections that indicate the company will generate $6.39 in profit per share in 2018. According to the most widely held opinion, Guardant Health’s current fiscal year is forecast to end with a loss of $6.47 in earnings per share. The consensus projection shows this. According to William Blair’s estimates, Guardant Health should generate earnings of $1.35 per share in the fourth quarter of 2022, $1.31 per share in the first quarter of 2023, $1.28 per share in the second quarter, $1.21 per share in the third quarter, and $1.21 per share in the fourth quarter. Additionally, the company should generate $1.20 per share in the third quarter and $5.00 per share in the fourth quarter of 2023.
Several other equity research analysts have discussed the company in recent comments, and some of those discussions have included the company. Cowen stated their intention to reduce their price target for Guardant Health from $83.00 to $70.00 in a research note that was published on Friday, December 16. The price target for Guardant Health was reduced by Credit Suisse Group on Friday, November 4, in a research note that was made public. The new price target is $70.00, down from $80.00. Despite this, the company was given an “outperform” rating by the company’s analyst firm. In a research note distributed on Friday, November 18, JPMorgan Chase & Co. lowered their price objective on shares of Guardant Health from $100.00 to $85.00. The previous price objective was $100.00.
The company also kept the stock’s rating at “overweight” throughout the process. In a research note made public on October 19, Craig Hallum initiated coverage for the shares of Guardant Health. They gave the company a “buy” recommendation and concluded that the price target should be $88,000. Last but not least, in a research note published on Monday, November 7, Stephens decreased their price target on shares of Guardant Health from $99.00 to $90.00 and categorized the stock as “overweight.” One of the equity research analysts recommends maintaining the stock in one’s portfolio, but the other fifteen recommend purchasing the stock or investing in it. According to information from Bloomberg.com, the stock is currently rated as having a “Moderate Buy” recommendation, and analysts have set their price objective for the stock at an average of $90.39 per share.
GH stock was listed for trading for the first time on Thursday for $30.77 per share. Guardant Health’s price can fall between $24.63 and $92.89 over a year. The debt-to-equity ratio was calculated to be 6.82, the current ratio was calculated to be 6.46, and the quick ratio was calculated to be 6.10. The simple moving average for the company over the past 50 days is $40.62, and the simple moving average over the past 200 days is $47.09, respectively. This company has a price-to-earnings ratio of -5.19, a beta value of 0.83, and a market capitalization of $3.15 billion.
The most recent quarterly earnings report for Guardant Health was released on November 3. This report can be found under the NASDAQ stock market’s ticker symbol NASDAQ: GH. The company reported earnings per share of $1.58, which was $0.31 less than the consensus estimate of $1.27 for the period provided by market analysts. The revenue for the quarter came in at $117.40 million, which was lower than the $118.18 million that analysts had anticipated would be for the quarter. Guardant Health had a negative net margin and a negative return on equity (140.58% and 145.58%), indicating that the company was losing money.
According to earlier reports concerning Guardant Health, on November 15, an employee of the company named Kumud Kalia sold 3,125 shares of the company’s stock. This information was obtained from publicly available sources. The shares were acquired at an average price of $51.87 per share, which resulted in the transaction having a total value of $162,093.75. The completion of the transaction has resulted in the insider acquiring ownership of 20,135 company shares with a combined value of $1,044,402.45, and these shares were the ones that the buyer of these shares purchased. Because of the filing with the SEC, information regarding the transaction is now available to the general public. On the website of the SEC, you can locate this particular file. Company insiders own 5.90% of the total shares currently outstanding.
Several significant investors have made recent modifications to their holdings of the s